Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd is a Canada-based medical device company. The Company is engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It is developing a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, imaging, and cardiotoxicity in oncology patients. The Company’s Ventripoint Medical System (VMS+) is a diagnostic aid that was developed to provide a point-of-care solution to better communicate the heart’s structure and function without the need for magnetic resonance imaging (MRI). VMS+ enhances ultrasound, providing three-dimensional (3D) technology that allows for visualization of all four chambers of the heart. The system’s proprietary Knowledge Based Reconstruction (KBR) technology creates 3D models of the heart and calculates volumes and ejection fractions equivalent to the gold-standard Magnetic resonance imaging (MRI).


TSXV:VPT - Post by User

Comment by snuff133on Mar 25, 2021 11:16am
154 Views
Post# 32875153

RE:RE:RE:RE:RE:Look at the big picture

RE:RE:RE:RE:RE:Look at the big pictureDear Friend;
 
I have approval to invite you to attend the BioPub event today at noon EST (see below). There is no charge but you will be asked your email address when you join.
 
Dr. KSS has been providing in-depth analysis of medical breakthrough companies for 8 years and has built up large following, which includes investors in 40 countries.
 
I presented to this group last fall and it is time for an update.  As an added bonus, Dr. Gregory Skinner, the head of echocardiolography at Glenfield Children’s Hospital in the UK will be joining the panel.  He will be relating his 5-year experience using the VMS in children and how it has allowed him to build a pan-European and Middle-East referral practice.  He sees children from many countries due to the ability of the VMS to obtain the same information as MRI without the negative impact children experience in MRI exams.
 
Being in the UK, he does the scans himself and also does cardiac MRI himself so can speak directly to why he finds the VMS so useful.  I am sure you will enjoy his perspective in this informal discussion with Dr. KSS and myself.
 
The session will be recorded and you can view it later on BioPUb website if noon is not convenient.  I will send out the link when I get it. 
 
Regards,

<< Previous
Bullboard Posts
Next >>